Varian Medical Systems (NYSE:VAR) announced that it received FDA 510(k) clearance for its Eclipse v16.1 treatment planning software.
Palo Alto, Calif.-based Varian’s Eclipse V16.1 software is designed to enhance the visibility of soft tissue and provide more accurate information about tissue density, allowing dosimetrists to plan more precisely as they go about performing proton therapy, according to a news release.
Varian said in the release that, through the release of the Eclipse v16.1 software and its intelligent treatment planning features, it can leverage the Siemens Healthineers Somatom Dect diagnostic imager with its dual x-ray energies capability.
Additionally, the Eclipse v16.1 is the first clinical release of GPU Monte Carlo proton dose calculation technology designed to allow clinicians to accelerate calculation speed and improve overall treatment planning efficiency.
“As a leader in proton therapy, Varian’s goal is to drive the next evolution of proton treatment planning by providing intelligent tools designed to improve plan quality, accelerate speed of dose calculations, and provide new levels of accuracy,” Varian president of proton solutions & chief growth officer Kolleen Kennedy said in the release. “With the launch of Eclipse v16.1 we continue to build on our strong foundation, providing the most sophisticated proton therapy planning solutions to our clinical users across the globe.”